Advances in the diagnosis, pathogenesis and treatment of CIDP

Nature Reviews Neurology

Volumn 7, Issue 9, 2011, Pages 507-517

  Dalakas, Marinos C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIGEN; AUTACOID; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ECULIZUMAB; FINGOLIMOD; HUMORAL ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NATALIZUMAB; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL PRACTICE; DEMYELINATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; ELECTROPHYSIOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; MAINTENANCE THERAPY; NERVE BIOPSY; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SCORING SYSTEM; T LYMPHOCYTE; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGE OF ONSET; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ELECTRODIAGNOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PLASMAPHERESIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 80052475047     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.121     Document Type: Review

References (129)

1. Austin, J. H. Recurrent polyneuropathies and their corticosteroid treatment. Brain 81, 11-192 (1958).
2. Dyck, P. J. et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc. 50, 621-637 (1975).
3. Prineas, J. W. & McLeod, J. G. Chronic relapsing polyneuritis J. Neurol. Sci. 27, 427-458 (1976).
4. Dalakas, M. C. in Clinical Immunology: Principles and Practice 3rd edn (eds Rich, R. R. et al.) 977-994 (Mosby Elsevier, Philadelphia, 2008).
5. Koller, H., Kieseier, B. C., Jander, S. & Hartung, H. P. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 352, 1343-1356 (2005).
6. Lauria, G. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17, 903-912 (2010).
7. Dalakas, M. C. & Engel, W. K. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann. Neurol. 10, 134-145 (1981). (Pubitemid 11120646)
8. Hughes, R. A. C., Allen, D., Makowska, A. & Gregson, N. A. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Periph. Nerv. Syst. 11, 30-46 (2006). (Pubitemid 43344973)
9. Vallat, J. M., Sommer, C. & Magy, L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 9, 402-412 (2010).
10. Said, G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul. Disord. 16, 293-303 (2006).
11. Dalakas, M. C, Teravinen, H. & Engel, W. K. Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies: incidence and management. Arch. Neurol. 41, 711-714 (1984). (Pubitemid 14124623)
12. Ryan, M. M., Grattan-Smith, P. J., Procopis, P. G., Morgan, G. & Ouvrier, R. A. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul. Disord. 10, 398-406 (2000). (Pubitemid 30433809)
13. Nevo, Y. et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 47, 98-102 (1996). (Pubitemid 26243867)
14. Sladky, J. T. & Teasley, J. E. What is the best initial treatment for childhood CIDP: corticosteroids or IVIg? Muscle Nerve 38, 1638-1643 (2008).
15. Saperstein, D. S. et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 22, 560-566 (1999). (Pubitemid 29214420)
16. Lewis, R. A., Sumner, A. J., Brown, M. J. & Asbury, A. K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 32, 958-964 (1982). (Pubitemid 12049457)
17. Sabatelli, M. et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J. Neurol. 248, 772-777 (2001). (Pubitemid 32802112)
18. Oh, S. J., Joy, J. L. & Kuruoglu, R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J. Neurol. Neurosurg. Psychiatry 55, 677-680 (1992).
19. Sinnreich, M. et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 63, 1662-1669 (2004). (Pubitemid 39507585)
20. Katz, J. S., Saperstein, D. S., Gronseth, G., Amato, A. A. & Barohn, R. J. Distal acquired demyelinating symmetric neuropathy. Neurology 54, 615-620 (2000). (Pubitemid 30082927)
21. Lunn, M. P., Manji, H., Choudhary, P. P., Hughes, R. A. & Thomas, P. K. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry 66, 677-680 (1999). (Pubitemid 29186982)
22. Laughlin, R. S., Dyck, P. J., Melton, L. J. 3rd, Leibson, C. & Ransom, J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73, 39-45 (2009).
23. Mygland, A. & Monstad, P. Chronic polyneuropathies in Vest-Agder, Norway. Eur. J. Neurol. 8, 157-165 (2001).
24. Iijima, M. et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J. Neurol. Neurosurg. Psychiatry 79, 1040-1043 (2008).
25. Rajabally, Y. A., Simpson, B. S., Beri, S., Bankart, J. & Gosalakkal, J. A. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 39, 432-438 (2009).
26. Chiò, A. et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J. Neurol. Neurosurg. Psychiatry 78, 1349-1353 (2007). (Pubitemid 350221415)
27. Uncini, A. et al. Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conductions are important in the differential diagnosis with diabetic polyneuropathy. Clin. Neurophysiol. 110, 705-711 (1999). (Pubitemid 29236400)
28. Chiò, A. et al. Comorbidity between CIDP and diabetes mellitus: only a matter of chance? Eur. J. Neurol. 16, 752-754 (2009).
29. Sharma, K. R. et al. Demyelinating neuropathy in diabetes mellitus. Arch. Neurol. 59, 758-765 (2002). (Pubitemid 34517757)
30. Rotta, F. T. et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 173, 129-139 (2000). (Pubitemid 30089597)
31. Mendell, J. R. et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 37, 1291-1294 (1987).
32. Sharma, K. R. et al. Chronic inflammatory demyelinating polyradiculoneuropathy associated with multiple sclerosis. J. Clin. Neuromuscul. Dis. 9, 385-396 (2008).
33. Dyck, P. J., Swanson, C. J., Low, P. A., Bartleson, J. D. & Lambert, E. H. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin. Proc. 57, 239-246 (1982). (Pubitemid 12091718)
34. Notturno, F. et al. Susceptibility to chronic inflammatory demyelinating polyradiculoneuropathy is associated to polymorphic GA repeat in the SH2D2A gene. J. Neuroimmunol. 197, 124-127 (2008).
35. American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).Neurology 41, 617-618 (1991).
36. Odaka, M., Yuki, N. & Hirata, K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome. J. Neurol. 250, 913-916 (2003). (Pubitemid 37041020)
37. Ruts, L., van Koningsveld, R. & van Doorn, P. A. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 65, 138-140 (2005). (Pubitemid 40967791)
38. Ruts, L., Drenthen, J., Jacobs, B. C. & van Doorn, P. A; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 74, 1680-1686 (2010).
39. Alshekhlee, A., Basiri, K., Miles, J. D., Ahmad, S. A. & Katirji, B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor- antagonists. Muscle Nerve 41, 723-727 (2010).
40. Bromberg, M. B. Review of the evolution of electrodiagnostic criteria for CIDP. Muscle Nerve 43, 780-794 (2011).
41. Brannagan, T. H. 3rd. The current diagnosis of CIDP: the need for biomarkers. J. Peripher. Nerv. Syst. 16, 3-13 (2011).
42. Lewis, R. A. & Sumner, A. J. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 32, 592-596 (1982). (Pubitemid 12119020)
43. Sommer, C. et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 65, 1924-1929 (2005). (Pubitemid 43970112)
44. Vital, C. et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct. Pathol. 24, 363-369 (2000). (Pubitemid 32060307)
45. Adachi, Y. et al. Brachial and lumbar plexuses in chronic inflammatory demyelinating polyradiculoneuropathy: MRI assessment including apparent diffusion coefficient. Neuroradiology 53, 3-11 (2011).
46. Nicolas, G. et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 25, 26-30 (2002). (Pubitemid 34019731)
47. Van den Bergh, P. Y. & Pieret, F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29, 565-574 (2004). (Pubitemid 38451348)
48. Magda, P. et al. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with CIDP. Arch. Neurol. 60, 1755-1759 (2003). (Pubitemid 37521632)
49. Chan, Y. C. et al. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 77, 114-116 (2006).
50. Haq, R. U. et al. Chronic inflammatory demyelinating polyradiculoneuropathy-a study of proposed electrodiagnostic and histologic criteria. Arch. Neurol. 57, 1745-1750 (2000).
51. Thaisetthawatkul, P., Logigian, E. L. & Herrmann, D. N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 59, 1526-1532 (2002). (Pubitemid 35387056)
52. De Sousa, E. A, Chin, R. L., Sander, H. W., Ltob, N. & Brannagean, T. H. 3rd. Demyelinating findings in typical and atypical CIDP: sensitivity and specificity. J. Clin. Neuromusc. Dis. 10, 163-169 (2009).
53. Rajabally, Y. A. et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J. Neurol. Neurosurg. Psychiatry. 80, 1364-1368 (2009).
54. Koski, C. L. et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 277, 1-8 (2009).
55. Bird, S. J., Brown, M. J., Shy, M. E. & Scherer, S. S. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 46, 822-824 (1996). (Pubitemid 26099655)
56. Tsuchida, T., Saxton, R. E., Morton, D. L. & Irie, R. F. Gangliosides of human melanoma. Cancer 63, 1166-1174 (1989). (Pubitemid 19074749)
57. Weiss, M. D. et al. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 51, 1738-1741 (1998). (Pubitemid 28565267)
58. Kiefer, R. et al. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J. Neurol. Neurosurg. Psychiatry 69, 362-368 (2000). (Pubitemid 30636240)
59. Murata, K. & Dalakas, M. C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 123, 1660-1666 (2000). (Pubitemid 30481189)
60. Hu, W. et al. Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology 68, 277-282 (2007). (Pubitemid 46148339)
61. Salomon, B. et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 194, 677-684 (2001). (Pubitemid 32844777)
62. Chi, L. J. et al. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 15, 345-356 (2010).
63. + regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 13, 54-63 (2008).
64. + regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 42, 667-677 (2009).
65. Hartung, H. P., Reiners, K., Schmidt, B., Stoll, G. & Toyka, K. V. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann. Neurol. 30, 48-53 (1991).
66. Kieseier, B. C. et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10 Brain 125, 823-834 (2002). (Pubitemid 34279777)
67. Mahad, D. J., Howell, S. J. & Woodroofe, M. N. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 73, 320-323 (2002).
68. Maimone, D., Annunziata, P., Simone, I. L., Livrea, P. & Guazzi, G. C. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 47, 55-61 (1993).
69. Oka, N. et al. Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy. Neurology 44, 946-950 (1994). (Pubitemid 24158815)
70. Renaud, S. et al. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 159, 203-214 (2005). (Pubitemid 40126194)
71. Lee, G., Xiang, Z., Brannagan, T. H. 3rd, Chin, R. L. & Latov, N. Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies. J. Neurol. Sci. 290, 115-122 (2010).
72. Yan, W. X., Taylor, J., Andrias-Kauba, S. & Pollard, J. D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 47, 765-775 (2000). (Pubitemid 30390197)
73. Dalakas, M. C. & Engel, W. K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch. Neurol. 37, 637-640 (1980). (Pubitemid 10018490)
74. Ilyas, A. A., Mitchen, F. A., Dalakas, M. C., Chen, Z. W. & Cook, S. D. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 107, 1111-1121 (1992).
75. Tagawa, Y., Yuki, N. & Hirata, K. Anti-SGPG antibody in CIDP: a nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve 23, 895-899 (2000). (Pubitemid 30354496)
76. Yan, W. X., Archelos, J. J., Hartung, H. P. & Pollard, J. D. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 286-292 (2001). (Pubitemid 32848730)
77. Dalakas, M., Houff, S. A., Engel, W. K., Madden, D. L. & Sever, J. L. CSF monoclonal bands in chronic relapsing polyneuropathy. Neurology 30, 864-867 (1980). (Pubitemid 10059147)
78. Tackenberg, B. et al. Impaired inhibitory Fc? receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788-4792 (2009).
79. Cifuentes-Diaz, C. et al. Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS ONE 6, e14533 (2011).
80. Lonigro, A. & Devaux, J. J. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 132, 260-273 (2009).
81. Pollard, J. D. & Armati, P. J. CIDP-the relevance of recent advances in Schwann cell/axonal neurobiology J. Peripher. Nerv. Syst. 16, 15-23 (2011).
82. Yan, W. X., Mathey, E., Yiannikas, C. & Pollard, J. Antineurofascin antibodies are present in patients with peripheral demyelinating neuropathies and mediate changes in nerve conduction in animals. J. Peripher. Nerv. Syst. 15, 288-289 (2010).
83. Iijima, M. et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73, 1348-1352 (2009).
84. Dyck, P. J. et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol. 11, 136-141 (1982). (Pubitemid 12162978)
85. Hughes, R. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 195-201 (2001). (Pubitemid 32738144)
86. Muley, S. A., Kelkar, P. & Parry, G. J. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch. Neurol. 65, 1460-1464 (2008).
87. van Schaik, I. N. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 9, 245-253 (2010).
88. Lopate, G., Pestronk, A. & Al-Lozi, M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch. Neurol. 62, 249-254 (2005). (Pubitemid 40204746)
89. Mendell, J. R. et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56, 445-449 (2001). (Pubitemid 32172866)
90. Hahn, A. F. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 51 (6 Suppl. 5), S16-S21 (1998). (Pubitemid 29001334)
91. Vermeulen M. et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56, 36-39 (1993). (Pubitemid 23062977)
92. Dyck, P. J. et al. A plasma exchange versus immune globulin infusion trial in chronic inflamatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36, 838-845 (1994). (Pubitemid 24370922)
93. van Doorn, P. A., Brand, A., Strengers, P. F., Meulstee, J. & Vermeulen, M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40, 209-212 (1990). (Pubitemid 20099423)
94. Hughes, R. A. C. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008).
95. Merkies, I. S. et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 72, 1337-1344 (2009).
96. Bril, V. et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 42, 492-497 (2010).
97. Latov, N. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol. 67, 802-807 (2010).
98. Lee, D. H. et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37, 406-409 (2008).
99. Dyck, P. J. et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 314, 461-465 (1986). (Pubitemid 16161945)
100. Hahn, A. F. et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double blind, sham-controlled, cross-over study. Brain 119, 1055-1066 (1996). (Pubitemid 26300708)
101. Hughes, R., Swan, A. & Doorn, P. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews, Issue 1 Art. No.: CD003280 doi:10.1002/14651858CD003280 (2003).
102. Mahdi-Rodgers, M., Swan, A. V., van Doorn, P. A. & Hughes, R. A. C. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for CIDP. Cochrane Database of Systematic Reviews, Issue 11 Art. No.: CD003280 doi:10.1002/14651858CD003280.pub3 (2010).
103. Dyck, P. J., O'Brien, P., Swanson, C., Low, P. & Daube, J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 35, 1173-1176 (1985). (Pubitemid 15003451)
104. Brannagan, T. H. 3rd et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58, 1856-1858 (2002). (Pubitemid 34663593)
105. Gladstone, D. E., Prestrud, A. A. & Brannagan, T. H. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 10, 11-16 (2005). (Pubitemid 40289577)
106. Good, J. L., Chehrenama, M., Mayer, R. F. & Koski, C. L. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51, 1735-1738 (1998). (Pubitemid 28565266)
107. Gorson, K. C., Amato, A. A. & Ropper, A. H. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63, 715-717 (2004). (Pubitemid 39100833)
108. Radziwill, A. J., Schweikert, K., Kuntzer, T., Fuhr, P. & Steck, A. J. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open-label study. Eur. Neurol. 56, 37-38 (2006). (Pubitemid 44359541)
109. Barnett, M. H., Pollard, J. D., Davies, L. & McLeod, J. G. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21, 454-460 (1998). (Pubitemid 28145321)
110. Hughes, R. A. et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 74, 651-657 (2010).
111. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 8, 158-164 (2009).
112. Dalakas, M. C. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul. Disord. 16, 223-236 (2006).
113. Vermeulen, M. & Van Oers, M. H. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 72, 127-128 (2002). (Pubitemid 34073115)
114. Kazmi, M. A., Mahdi-Rogers, M. & Sanvito, L. Chronic inflammatory demyelinating polyradiculoneuropathy: a role for haematopoietic stem cell transplantation? Autoimmunity 41, 611-615 (2008).
115. Marsh, E. A. et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J. Neurol. 257, 913-919 (2010).
116. Dalakas, M. C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4, 557-567 (2008).
117. Dalakas, M. C. Inhibition of B cell functions: implications for neurology. Neurology 70, 2252-2260 (2008).
118. Benedetti, L. et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J. Neurol. Neurosurg. Psychiatry 82, 306-308 (2011).
119. Münch, C., Anagnostou, P., Meyer, R. & Haas, J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus J. Neurol. Sci. 256, 100-102 (2007). (Pubitemid 46560632)
120. Briani, C. et al. Rituximab-responsive CIDP. Eur. J. Neurol. 11, 788 (2004).
121. Kosmidis, M. & Dalakas, M. C. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther. Adv. Neurol. Disord. 3, 93-105 (2010).
122. Fitzpatrick, A. M. et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 16, 84-91 (2011).
123. Wolf, C. et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 67, 881-883 (2010).
124. Dalakas, M. C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr. Opin. Neurol. 12, 403-409 (1999). (Pubitemid 30028737)
125. Dalakas, M. C. Potential biomarkers for monitoring therapeutic responses to IVIg and other therapies in CIDP. J. Peripher. Nerv. Syst. 16, 63-67 (2011).
126. Comi, C. et al. Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 11, 53-60 (2006). (Pubitemid 43344975)
127. Tanighuchi, J. et al. Inflammatory demyelinating polyneuropathy sera inhibit axonal growth of mouse dorsal root ganglion neurons by activation of Rho-kinase. Ann. Neurol. 66, 694-697 (2009).
128. Gorson, K. C. et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J. Peripher. Nerv. Syst. 15, 326-333 (2010).
129. Hartung, H. P., Lehmann, H. C. & Willison, H. G. Establishing common clinical research standards for CIDP. Nat. Rev. Neurol. 7, 250-251 (2011).